The myelodysplastic/myeloproliferative disorders: The interface

Hematology/Oncology Clinics of North America

Volumn 17, Issue 5, 2003, Pages 1095-1100

  Bennett, John M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ERYTHROPOIETIN; FAZARABINE; HYDROXYUREA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TOPOTECAN;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTOPENIA;

EID: 0141506861     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00086-8     Document Type: Review

References (19)

1. Bruming RD, Matutes E, Harris NL, Flandrin G, Vardiman J, Bennett J, et al. Acute myeloid leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 77-80.
2. Cogswell PC, Morgan R, Dunn M, et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989;74:2629-33.
3. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
4. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic leukemia, atypical chronic myeloid and chronic myelomonocytic leukemia: proposals by the French-American-British Cooperative leukemia Group. Br J Haematol 1994;87:746-54.
5. Kantarjian HM, Shtalrid M, Kurzrock R, et al. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med 1988;85:639-44.
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
7. Onida F, Kantarjian HM, Ball G, et al. The dysplastic versus proliferative classification dilemma of chronic myelomonocytic leukemia: a retrospective single institution analysis of 264 patients [abstract 2607]. Blood 2001;98:622a.
8. Voglova J, Chrobak L, Neuwirtova R, Malaskova V, Straka L. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia-distinct subgroups or two stages of the same disease? Leuk Res 2001;25:493-9.
9. Cheson BD. The myelodysplastic syndromes: current approaches to therapy. Ann Intern Med 1990;112:932-41.
10. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a metaanalysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
11. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long standing refractory anemia of patients with myelodysplastic syndromes. Blood 2001;98:958-65.
12. Miller KB, Kim K, Morrison FS, et al. The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: a Phase III intergroup study. Ann Hematol 1992;65:162-8.
13. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7:21-9.
14. Beran M, Shen Y, Kantarjian H, et al. High dose chemotherapy in high risk myelodysplastic syndrome: co-variate-adjusted comparison of five regimens. Cancer 2001;92:1999-2015.
15. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996;87:51-8.
16. Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in advanced chronic myelomonocytic leukemia. Blood 1996;88:2480-7.
17. Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88:2473-9.
18. Beran M, Onida F, Cortes JE, et al. Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia [abstract]. Blood 2001;98:624a.
19. Kroger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation for adult chronic myelomonocytic leukaemia: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002;118:67-73.